With $379M Deal For Ocata, Astellas Buys Stem Cells For Eye Diseases – Xconomy
Xconomy |
With $379M Deal For Ocata, Astellas Buys Stem Cells For Eye Diseases
Xconomy Japanese drug firm Astellas Pharma announced late Monday it has agreed to buy Ocata Therapeutics (NASDAQ: OCAT), which is developing regenerative medicines for eye diseases. It's an all-cash deal worth $379 million, with the Astellas offer of $8.50 a … Astellas Pharma to Acquire Ocata Therapeutics Astellas to Acquire Ocata Therapeutics |
